Main Menu

FDA-backed CBD drug brings in $296 million in ‘incredible launch year,’ GW Pharma CEO says

FDA-backed CBD drug brings in $296 million in ‘incredible launch year,’ GW Pharma CEO says

Tyler Clifford | Jan 16 2020

Preliminary sales figures for the first cannabis-based medicine in the United States are in and they’re telling a bullish story, according to GW Pharmaceuticals CEO Justin Gover.

Epidiolex, which contains cannabidiol to treat severe forms of epilepsy, brought in $104 million in net sales in the fourth quarter and a total of $296 million in 2019 across the globe, the British pharmaceutical company preannounced for its quarterly and full-year performances.

“It’s an incredible launch year for any medication [that] I think proves that this kind of medicine is really making a difference to patients,” Gover told CNBC’s Jim Cramer in a “Mad Money” interview. “It shows real value to the health-care system, and it sets us up, I think, in a very nice way for what should be another great year for us in 2020.”

FDA-backed CBD drug brings in $296 million in ‘incredible launch year,’ GW Pharma CEO says






Comments are Closed